TNNI2

Across TCGA pan-cancer cohorts, TNNI2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TNNI2 data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TNNI2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TNNI2 expression acts as an unfavorable survival marker.

LUAD, STAD, and COAD are the cancer types where TNNI2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.227	0.673	.010	15	view →
STAD	OS	Median	IV	0.099	0.509	.002	12	view →
COAD	OS	Median	All	0.500	0.871	.013	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TNNI2–LUAD (OS)

Open the LUAD breakdown →